Patients with diabetes in general show increased susceptibility to bacterial infections but the mechanisms by which this occurs are poorly understood[@b1][@b2][@b3]. In Thailand, type 2 diabetes mellitus (DM) is the most common underlying condition associated with melioidosis, a serious infection caused by the soil-dwelling Gram-negative bacillus, *Burkholderia pseudomallei*[@b4]. This infectious disease is endemic in Southeast Asia and Northern Australia. In Northeast Thailand, melioidosis accounts for 20% of cases of community-acquired septicemia with a mortality rate of 50%[@b5][@b6]. Animal models have shown that polymorphonuclear neutrophils (PMNs) play a critical role in *B. pseudomallei* infection[@b7][@b8]. Previously, we have demonstrated that PMNs from diabetic patients had impaired functions, including phagocytosis, migration, and apoptosis, in response to *B. pseudomallei* infection[@b9]. However, the cytokine response has not yet been elucidated in melioidosis, even though it is one of the crucial functions of PMNs[@b10].

It has been demonstrated that Toll-like receptors (TLRs) play a critical role in melioidosis pathogenesis[@b11] and MyD88, the key TLR adaptor protein, regulates tumor necrosis factor (TNF)-α production in response to *B. pseudomallei*[@b12]. TLR ligands and TNF-α are both potent activators of the transcription factor NF-κB, the main positive regulator of transcription of a wide range of pro-inflammatory cytokine mRNA including precursor interleukin (IL)-1β (pro-IL-1)[@b13]. However, this pro-form of IL-1β is inactive and requires activation via a protein complex called the inflammasome[@b14][@b15]. The mature form of IL-1β induces the production of a wide range of cytokines and chemokines such as CC-chemokine ligand 2 (CCL2), CCL3 and CXC chemokine ligand 8 (also known as IL-8) through NF-κB activation[@b15][@b16][@b17].

Caspase-1-dependent immune mechanisms play an essential role in resistance against *B. pseudomallei* infection in murine macrophages[@b18]. Reduction or inhibition of inflammasome activation in PMNs may contribute to the increased susceptibility to this infection[@b19]. Additionally, in vivo data showed that PMNs of diabetic patients compared to healthy subjects presented an impaired ability to produce sufficient key cytokines, especially IL-1β in response to *E. coli* LPS[@b20]. Those findings then led us to determine the effect of DM treatment by glibenclamide (international nonproprietary name), also known as glyburide (United States adopted name), which is a common treatment for DM in the World Health Organization Model List of Essential Medicines. Glibenclamide works by inhibiting ATP-sensitive potassium channels in pancreatic beta cells resulting in an increase in intracellular calcium and subsequent stimulation of the release of insulin from beta cells and increased glucose uptake into the cells. However, glibenclamide is also known to have an inhibitory effect on inflammasome assembly[@b21]. Our results suggest possible mechanisms involved in the regulation of cytokine production in response to *B. pseudomallei* in PMNs of diabetic patients who had been treated with glibenclamide.

RESULTS
=======

PMNs of diabetic subjects exhibit reduced pro-inflammatory cytokine production in response to *B. pseudomallei*, LPS, flagellin, and TNF-α
------------------------------------------------------------------------------------------------------------------------------------------

First, we evaluated the kinetics of proinflammatory cytokine production and found that TNF-α could be detected in supernatants with similar levels and kinetics for PMNs from diabetic and healthy subjects ([Figure 1A](#f1){ref-type="fig"}). In contrast, significantly lower levels of IL-1β and IL-8 were secreted by PMNs from diabetic patients ([Figure 1A](#f1){ref-type="fig"}; *P* \< 0.001) and observed over a range of 0.3--10 multiplicity of infection (MOI) ([Figure 1B](#f1){ref-type="fig"}; *P* \< 0.05), indicating that this phenotype is unlikely to result from reduced contact between PMNs of diabetic subjects and the bacteria. We also confirmed that there was no difference in bacterial loads and PMN viability between the two subjects groups over the time course investigated (see [Supplementary Fig. S3 and S4](#s1){ref-type="supplementary-material"} online).

In order to confirm whether recognition of bacterial components by PMNs from diabetic subjects was impaired, we investigated their ability to produce IL-1β and IL-8 after stimulation with defined TLR ligands; LPS and flagellin are recognized by TLR4 and TLR5 respectively, and TNF-α. In PMNs from both diabetic and healthy subjects, less IL-1β and IL-8 were induced in response to TLR ligands compared to *B. pseudomallei* infection at the concentrations used. These data indicate that *B. pseudomallei* is capable of activating cytokine production from PMNs through pathways other than TLR4, TLR5, and the TNF-α receptor. These data are also consistent with our previous studies showing that LPS could stimulate purified PMNs to produce cytokines[@b22]. Moreover, they provide compelling evidence that PMNs from diabetic subjects fail to produce IL-1β and induce less IL-8 upon activation of such receptors compared with PMNs from healthy controls.

*B. pseudomallei* activates PMNs to produce IL-1β via a caspase-1-dependent pathway
-----------------------------------------------------------------------------------

In macrophages, IL-1β is proteolytically processed to its active form by caspase-1, in response to *B. pseudomallei*[@b14][@b15][@b16]. In PMNs, we found that caspase-1 inhibition significantly reduced IL-1β and IL-8 production in a dose-dependent manner ([Figure 2A](#f2){ref-type="fig"}; *P* \< 0.05), suggesting that *B. pseudomallei* triggers IL-1β processing through the activation of a caspase-1-dependent pathway. Western blot analysis confirmed that the activated 17.5-kDa fragment of IL-1β was detected from supernatant of infected healthy PMNs ([Figure 2B](#f2){ref-type="fig"} and [Supplementary Fig. 5S](#s1){ref-type="supplementary-material"} online). Real-time quantitative RT-PCR indicated that both LPS and *B. pseudomallei* induced transcription of IL-1β, IL-8, caspase-1, and NLRP3 genes relative to medium alone ([Figure 2C](#f2){ref-type="fig"}); however, transcripts of these genes were significantly less abundant in PMNs from diabetic subjects upon treatment with LPS or *B. pseudomallei* ([Figure 2C](#f2){ref-type="fig"}; *P* \< 0.05). These results suggest that the inflammasome-associated pathway is impaired in PMNs from diabetic subjects.

IL-1β induces IL-8 production in PMNs in response to pathogens
--------------------------------------------------------------

We found that IL-8 production in PMNs from diabetic subjects was induced by rIL-1β in a dose-dependent manner, although at lower levels than observed with PMNs from healthy donors ([Figure 3A](#f3){ref-type="fig"}; *P* \< 0.001 and [Supplementary Fig. S1](#s1){ref-type="supplementary-material"} online). We further evaluated whether additional IL-1β could compensate reduced IL-8 production of diabetic subjects. We found that rIL-1β induced IL-8 production in *B. pseudomallei* infected PMNs from both healthy and diabetic subjects, despite the lower level of IL-8 released by PMNs from diabetic subjects. This suggests that signaling downstream of the IL-1 receptor (IL-1R) could be perturbed in PMNs from diabetic subjects.

Next, we treated PMNs from healthy donors with anti-human IL-1RI antibody[@b23] to inhibit IL-1 signaling during infection with *B. pseudomallei* in vitro. IL-1β and IL-8 levels were decreased in a dose-dependent manner by IL-1RI-specific antibody, whereas levels of TNF-α were not altered ([Figure 3B](#f3){ref-type="fig"}; *P* \< 0.05). The similar blocking effect of anti-IL-1RI at a concentration of 20 μg/ml on cytokine release in response to *B. pseudomallei* infection was observed following infection with the other Gram-negative bacteria, *S. enterica* serovar Typhimurium and *E. coli* ([Figure 3C](#f3){ref-type="fig"}; *P* \< 0.05 and [Supplementary Fig. S2](#s1){ref-type="supplementary-material"} online). In combination with our previous experiments, we conclude that PMNs from diabetic subjects have reduced ability to produce IL-8 upon exposure to *B. pseudomallei* and other Gram negative bacteria as a result of both their impaired production of and response to IL-1β production.

Glibenclamide, but not metformin reduces IL-1β and IL-8 production
------------------------------------------------------------------

More than half of the patients with type 2 diabetes in endemic areas of melioidosis are prescribed glibenclamide or a combination of glibenclamide and metformin to control blood glucose levels [](#t1){ref-type="table"}([Table 2](#t2){ref-type="table"}). To determine whether the impaired cytokine response to *B. pseudomallei* was an intrinsic property of the diabetic state or also reflected aspects of their treatment, PMNs were incubated with the drugs at a dose comparable to the range of glibenclamide given during oral therapy to the human subjects[@b24][@b25]. Glibenclamide impaired IL-1β and IL-8 production by PMNs from healthy subjects infected in vitro with *B. pseudomallei* in a concentration-dependent manner ([Figure 4A](#f4){ref-type="fig"}; *P* \< 0.05). In contrast, metformin did not affect the production of IL-1β and IL-8 production. Addition of glibenclamide and metformin together produced the same dose-dependent effects as glibenclamide alone ([Figure 4A](#f4){ref-type="fig"}; *P* \< 0.05) indicating that it was the effect of glibenclamide rather than metformin that reduced production of these two cytokines from PMNs. A similar effect was observed upon LPS activation and PMA treatment ([Figure 4B](#f4){ref-type="fig"}). However, IL-8 levels were significantly reduced in proportion to the increasing concentrations of glibenclamide. When using PMNs from diabetic subjects, glibenclamide reduced IL-8 production upon *B. pseudomallei* infection or PMA activation, but not following LPS activation ([Figure 4C](#f4){ref-type="fig"}). Of note, the level of IL-1β produced by PMNs from diabetic subjects was lower than the limit of detection by ELISA (data not shown). Our data confirm that treatment of PMNs with glibenclamide reduces cytokine production in response to *B. pseudomallei* infection and other stimuli.

Decreased IL-1β and IL-8 production by PMNs from diabetic subjects associated with glibenclamide treatment
----------------------------------------------------------------------------------------------------------

To assess whether specific drug treatment regimes for diabetic subjects influence cytokine production by their PMNs, we compared the cytokine production of PMNs isolated from diabetic subjects (see [Table 2](#t2){ref-type="table"} for details of subjects). These subjects had similar levels of glycemic control whichever anti-diabetic drug treatment was used ([Table 2](#t2){ref-type="table"}). As shown in [Figure 5B](#f5){ref-type="fig"}, significantly lower levels (*P* \< 0.05) of IL-1β and IL-8 were produced by PMNs from diabetic subjects who were being treated with glibenclamide compared to PMNs from patients yet to receive treatment (NDM group). In contrast, levels of TNF-α were not significantly different between the various subject groups (data not shown), which indicated that glibenclamide specifically affects IL-1β and IL-8 production by PMNs in response to *B. pseudomallei* infection.

Taken together, our findings demonstrate that PMNs from diabetic subjects who are treated with glibenclamide have impaired ability to produce IL-1β and IL8 in response to *B. pseudomallei* compared to those from healthy donors.

Discussion
==========

Diabetes is the strongest primary risk factor in melioidosis but it is not known which immunological processes underlie the susceptibility of diabetic patients to *B. pseudomallei* infection. According to our previous study, not only the impairment of PMN functions in diabetic patients[@b9], but also deterioration in early cytokine response is a problem. In this study, possible mechanisms concerned with the regulation of cytokine production in response to *B. pseudomallei* have been demonstrated in PMNs of diabetic patients. Our first observation was that PMNs from diabetic subjects infected with *B. pseudomallei* showed reduced production of IL-1β and IL-8 but maintained TNF-α production. These results differ from those in other studies showing that with *E. coli* LPS stimulation, PMNs from diabetic subjects produced higher amounts of TNF-α, IL-1β, and IL-8 than healthy controls[@b26]. Moreover, another study using a whole-blood stimulation assay has shown that the level of IL-8 was elevated in individuals with type 2 diabetes[@b27]. These may be due to difference in the experimental system used, as the study did not mention how DM was controlled among their donors or did not specify generic names of medications.

In addition to controlling IL-1β production in PMNs, we have shown that *B. pseudomallei* induced PMNs to produce IL-1β through caspase-1-dependent pathway. Previous studies on the inflammasome activation by *B. pseudomallei* have shown that NLRC4 (Nod-like receptor family) detects the basal body rod component of the type III secretion systems apparatus (rod protein) from *B. pseudomallei* (BsaK)[@b28]. However, PMNs express NLRP3 mRNA but not NLRC4 mRNA, therefore production of IL-1β is primarily dependent on the NLRP3 inflammasome[@b29]. Although previous studies show that the inflammasome is normally associated with macrophages in response to *B. pseudomallei* infection[@b30], in our samples, the contribution of monocyte/macrophage contamination to IL-1β production is likely to be negligible. These suggest that PMNs are an important source of IL-1β in PMN dominant foci. We have confirmed here that *B. pseudomallei* activated PMNs to upregulate the levels of mRNA expressions of IL-1β, caspase-1, and NLRP3 genes. We also found that these expression levels from poor glycemic control diabetic patients treated with glibenclamide were significantly lower than healthy controls. These results suggest that glibenclamide might affect initial IL-1β production through regulation of transcription or translation. It is also known that IL-1β induces chemokines, such as IL-8, MCP-1, and RANTES, involved in PMN recruitment to infection sites[@b31]. In a mouse model, IL-1β led to excessive recruitment of PMNs in the lungs during *B. pseudomallei* infection[@b29]. Unsurprisingly, when we blocked caspase-1 activity in PMNs, not only did it reduce IL-1β production, but also completely suppressed IL-8 production. This suggests that caspase-1 may be an important mediator for PMNs to produce IL-8 in response to *B. pseudomallei*.

We further demonstrated here that the blockage of IL-1 receptor partially reduced IL-8 secretion from PMNs whereas the level of TNF-α was not influenced, which attested to the specificity of inflammasome activation. This suggests that the inflammasome activation in PMNs could induce IL-8 production independently of IL-1β. Studies in humans have also shown that inhibition of the function of IL-1 using the IL-1R antagonist IL-1ra is associated with increased susceptibility to bacterial infection[@b32]. Our results were in accordance with recent studies of early cytokine response in the diabetic mouse model of melioidosis which demonstrated impaired proinflammatory cytokine response; moreover, PMN predominant infiltration at the site of infection was more extensive in diabetic mice[@b33]. However, it is not feasible to confirm whether reduced IL-8 production could influence migration of PMNs to infected foci or not in human patients. Therefore, we propose that reduced IL-1β and IL-8 axis, which is a strong activator of PMN functions, may result in impaired activation of PMNs at the infection site, and reduced bacterial killing as suggested in the diabetic mouse model[@b33]. These suggestions are consistent with the evidence in humans shown that diabetes is the most common underlying condition associated with melioidosis[@b4].

Moreover, we show here that medication for diabetes was associated with decreased cytokine production, especially with glibenclamide treatment. As previously shown, this drug had an inhibitory effect on an inflammasome assembly[@b21]. Our data from this study indicate that both gene expression and protein of IL-1β in diabetic subjects were reduced. We suggest that glibenclamide may directly affect the modification of IL-1β or inflammasome related gene expression. These may explain how glibenclamide administration disrupts the ability to produce IL-1β under the poor glucose control of DM. There is not only the direct effect on IL-1β production but the sulfonylureas have also been shown to act as an antagonist of the CXCR2[@b34] and to inhibit PMN migration in mice with sepsis[@b35]. This drug might have an effect on the failure of PMN migration to the focus of infection, which could increase susceptibility and the risk of severe sepsis in polymicrobial infections, as well as in melioidosis. However, It has been reported that there was reduced mortality in melioidosis patients with preexisting DM who were treated with glibenclamide[@b36]. These patients would not have an undesirable overinflammatory state in septic melioidosis; these observations may be explained, at least in part, by our data suggesting that glibenclamide could directly decrease IL-1β and IL-8 production of PMNs infected with *B. pseudomallei*. So impaired functions of PMNs might be due, in part, to the reduction of IL-1β linked to the effect of glibenclamide during melioidosis. Nevertheless, glibenclamide treatment with poor control of blood glucose level may place diabetic patients at a disadvantage for onset or a recurrence of *B. pseudomallei* infection.

More than half of diabetic patients in an endemic area of melioidosis in Northeast Thailand have been treated with glibenclamide alone or both glibenclamide and metformin. We found no evidence that metformin, another anti-diabetic drug, directly affects PMN cytokine production. So far, studies of the contribution of metformin to inflammasome activation have provided indirect evidence suggesting that the beneficial effects of metformin in DM might arise from its ability to regulate the inflammasome by enhancing autophagic activity[@b37][@b38]. Further understanding of the effects of anti-diabetes drugs on PMN functions may lead to reduced risks of infection by some other intracellular bacterial pathogens in diabetic patients.

Taken together, the data point to possible mechanisms of impaired cytokine response in PMNs from diabetic subjects infected with *B. pseudomallei*. Our findings are the first to raise the intriguing mechanism that glibenclamide may act as one of the crucial factors involved in the impairment of innate immunity and the manifestation of bacterial infections in poorly controlled diabetes mellitus.

Methods
=======

Patients
--------

We enrolled 46 diabetic and 32 healthy Thai subjects. All subjects were defined here as aged over 35 years and matched by sex and place of residence (Northeast, Thailand)[@b9]. None of the subjects had any signs of acute infectious disease in the three months prior to sampling. The healthy control group consisted of subjects with normal fasting blood glucose levels (3.9--6.2 mmol/L) and normal glycosylated hemoglobin A1c (HbA1c) levels (\<6.5%). HbA1c was detected by immunoturbidimetric assay and the results were reported following guidelines of the National Glycohemoglobin Standardization Program. The healthy subjects were recruited from both blood bank donors and healthy university staff, who live in the same endemic area as patients. The patients involved in this study had been treated with either glibenclamide, metformin, or both. Patients defined as no treatment group were newly diagnosed with diabetic mellitus (NDM), as defined by World Health Organization criteria[@b39]. Diabetic patients from each group exhibited very poor glycemic control on the basis of HbA1c levels (\>8.5%) previously described[@b9]. Unless stated otherwise, only diabetic subjects who had been treated with glibenclamide or metformin alone or a combination of glibenclamide and metformin were enrolled. All diabetic subjects were treated at the Outpatient Department, Khon Kaen Hospital and Khon Kaen Primary Medical Service. The exclusion criteria for both healthy and diabetic volunteers were impaired renal function which causes secondary immunosuppression, defined by a serum creatinine level of ≥0.11 mmol/L. All subjects had creatinine level \<0.11 mmol/L and the characteristics of all subjects are shown in [Table 2](#t2){ref-type="table"}. The collection and analysis of all samples was approved by the Khon Kaen University Ethics Committee for Human Research and the Khon Kaen Hospital Ethics Committee. All subjects provided written informed consent. Each experiment was performed with both healthy and matching DM subjects, generally one healthy versus one matching DM subject, unless stated otherwise.

Microorganisms
--------------

*B. pseudomallei* K96243 strain was grown to mid-logarthmic phase at 37°C in Luria-Bertani (LB) broth. Bacterial growth was assessed by measuring the optical density at 600 nm. Generally, an absorbance index of 1 was equivalent to10^9^ CFU/mL of bacteria and the number of viable bacteria (colony-forming units) in inocula was determined by retrospective plating of serial ten-fold dilutions on LB agar. There was no outlier of the variation of the inoculating dose within batches. Live *B. pseudomallei* was handled under the US Centers for Disease Control regulations for research at containment level 3. *Salmonella enterica* serovar Typhimurium ATCC 13311 and *Escherichia coli* ATCC 25422 were obtained from Microbial Culture Collection Center, Thailand, grown overnight in LB broth at 37°C, and enumerated as above.

PMN isolation and stimulation
-----------------------------

We isolated PMNs from heparinized venous blood by dextran sedimentation and Ficoll-Paque centrifugation, as previously described[@b9], and the resulting cell preparation was confirmed to consist of \>95% PMNs by flow cytometry and by CD14 staining. The morphology of PMNs was also determined by Giemsa staining and microscopy, and the cell viability was \>98%, as determined by trypan blue exclusion. Unless stated otherwise, purified PMNs at a concentration of 2.5 × 10^6^ cells/ml in RPMI 1640 culture medium (Gibco) were incubated at 37°C, 5% CO~2~ for 16 h with *B. pseudomallei* at an MOI of 0.3:1 or activated with 300 ng/ml of LPS (from *E coli*, Sigma), 300 ng/ml of *B. pseudomallei* flagellin (BPSL3319, obtained from Dr. Philip L. Felgner, University of California, Irvine, USA), 30 ng/ml of recombinant human TNF-α (BD Biosciences), or 5 ng/ml of human rIL-1β (eBiosciences). In some experiments, the following reagents were added to PMNs for 1 h prior to infection with *B. pseudomallei* (MOI 0.3:1), or treatment with LPS (300 ng/ml), or 3 ng/ml of phorbol 12-myristate 13-acetate (PMA, Sigma). The reagents were 10 μg/ml caspase-1 inhibitor VI (Calbiochem), 20 μg/ml anti-human IL-1RI neutralizing antibody (R&D systems), or anti-diabetic drugs: 50 μM glibenclamide (Sigma) which is comparable to human blood concentration achieved following a 20 mg oral dose[@b40], or 50 μM metformin (Sigma) which is comparable to human blood concentration achieved following a 2000 mg oral dose[@b41].

Cytokine measurement
--------------------

When indicated, we assessed IL-1β, IL-8, and TNF-α concentration in the supernatant of PMN cultures in duplicate by ELISA (BD Biosciences) according to the manufacturer\'s instructions. The supernatants were stored at −80°C until the cytokine assay.

Reverse transcription and real time PCR analysis
------------------------------------------------

Total RNA was extracted using the RNeasy Mini Kit (Qiagen). Reverse transcription reactions were performed using Improm-II reverse transcriptase (Promega) according to the manufacturers\' instructions. Transcript levels were determined by SYTO9-based real-time PCR using an ABI 7500 Real-Time PCR System (Applied Biosystems). *GAPDH* transcripts were quantified as an internal control. The relative expression level was calculated by the 2−ΔΔ*C*t method. The sequences of all transcripts in this study were retrieved from PubMed ([www.ncbi.nln.nih.gov](http://www.ncbi.nln.nih.gov)) and specific primers (listed in [Table 1](#t1){ref-type="table"}) were designed using the NCBI primer designing tool. We also confirmed the melting peak analysis of real time PCR products specific to individual gene.

Western blot analysis of mature IL-1β
-------------------------------------

The supernatants of PMN cultures were collected after 16 h. The samples were concentrated using nanosep 3 k omega kit (Pall Corporation) and lysed in 2× sample buffer in the presence of protease inhibitors. Proteins were resolved by SDS-PAGE and transferred to polyvinylidene fluoride membranes (Pall Corporation). Membranes were blocked with 5% (w/v) skimmed milk in Tris-buffered saline with 0.1% Tween-20 (TBST) and were incubated with rabbit primary antibodies against human IL-1β (Cell Signaling, 1: 1000 dilution) for 1 h at room temperature. After three washes in TBST, the membranes were incubated with horseradish-peroxidase-conjugated goat anti-rabbit IgG (Cell Signaling, 1: 2000 dilution) for 1 h at room temperature. After three TBST washes, antibody binding was visualized by enhanced chemiluminescence (Pierce).

Statistics
----------

Statistical analysis (two way ANOVA and one way ANOVA with post test Bonferroni and paired *t* test) was performed by using Graphpad PRISM statistical software version 5 (Graphpad 5). P values ≤0.05 were taken to be significant.
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![PMNs from diabetic subjects exhibit reduced pro-inflammatory cytokine production.\
(A) Purified PMNs of 3 healthy (closed circles) and 3 DM (open circles) subjects (one glibenclamide alone and two combination treatment) were infected with *B. pseudomallei* at MOI of 0.3:1 for 1, 2, 4, 16, and 24 h. TNF-α, IL-1β, and IL-8 were measured in supernatants by ELISA. The circles indicate means ± s.d. Asterisks indicate significant differences between healthy and DM subjects at the same time point by paired *t* test. (B) Purified PMNs from 2 healthy and 2 DM subjects (one glibenclamide and one combination treatment) stimulated for 16 h with various *B. pseudomallei* MOIs, various concentrations of LPS, flagellin, or the recombinant human TNF-α (rTNF-α). Cell supernatants were analyzed for IL-1beta and IL-8 by ELISA. Error bars represent means ± s.d. Data represents one of two independent experiments with similar results. Asterisks indicate significant differences between healthy and DM subjects at the same concentration by paired *t* test. \*\**P* \< 0.01, and \**P* \< 0.05. ns, non significant.](srep03363-f1){#f1}

![*B. pseudomallei* activate PMNs to produce IL-1β via a caspase1-dependent pathway.\
(A) IL-1β and IL-8 were produced from purified PMNs of 3 healthy and 3 DM subjects (two glibenclamide alone and one combination treatment) treated with various concentrations of caspase-1 inhibitor (inh) before being infected with *B. pseudomallei* at an MOI of 0.3:1 for 16 h. The data represent one of three independent experiments with similar results expressed as means ± s.d. Asterisks indicate significant differences between no caspase-1inh and infected with *B. pseudomallei* by Two Way ANOVA. (B) Purified PMNs from healthy subject and DM who had been treated with combination drug were infected for 1 h with *B. pseudomallei* and IL-1β in supernatant was assessed by Western blot using antibody specific for IL-1β. The full-length blots on the same conditions are presented in [Supplementary Figure S5](#s1){ref-type="supplementary-material"}. (C) Purified PMNs were co-cultured for 4 h with *B. pseudomallei* at an MOI of 0.3:1 or LPS at 300 ng/ml. Expression of cytokine-related mRNA (IL-1beta, IL-8, caspase1 and NLRP3) was detected by using real-time PCR. Representative data from one experiment is expressed as means ± s.d. Asterisks indicate significant differences between the open columns compared diabetic to healthy subjects at the same condition by paired *t* test. \*\*\**P* \< 0.001 \*\**P* \< 0.01, and \**P* \< 0.05. No asterisk or ns, non significant.](srep03363-f2){#f2}

![IL-1β induces IL-8 production in response to pathogens.\
(A) Purified PMNs of 3 healthy and 3 diabetic subjects (two glibenclamide alone and one combination treatment) were pretreated for 30 min with various concentrations of the recombinant human IL-1β (rIL-1β) before being infected with *B. pseudomallei* at an MOI of 0.3:1 or with added medium for 16 h; level of IL-8 in the supernatants was measured. Data are expressed as means ± s.d. Asterisks indicate significant differences between between healthy and diabetic subjects at the same time point by paired *t* test. (B) IL-8, IL-1β, and TNF production by PMNs from 3 healthy subjects were determined by ELISA in the supernatant harvested after PMNs were pretreated for 60 min with anti-human IL-1 RI antibody and infected with *B. pseudomallei* at MOI of 0.3:1 for 16 h. Data were contained 3 healthy subjects as means ± s.d., and samples were assayed in duplicate. Asterisks indicate significant differences between antibody treatment and *B. pseudomallei-*infectection alone by One way ANOVA. (C) PMNs treated as in (B) then infected with *S. enterica serovar Typhimurium* (Sal) or *E. coli* at the same MOI. Asterisks indicate significant differences between treatment with IL-R1 and medium alone in the same conditions by paired *t* test. \*\*\**P* \< 0.001 \*\**P* \< 0.01, and \**P* \< 0.05. No asterisk or ns, non significant.](srep03363-f3){#f3}

![Glibenclamide but not metformin reduces IL-1β and IL-8 production.\
(A) Purified PMNs from healthy donors were treated for 1 h with glibenclamide and/or metformin at concentrations as indicated before infection with *B. pseudomallei* (Bps) at an MOI 0.3:1 for 16 h and IL-1β and IL-8 levels in supernatants were measured by ELISA. Data for 3 healthy subjects are means ± s.d, and samples were assayed in duplicate. Asterisks indicate significant differences between treated and non-treated groups by One Way ANOVA. (B, C) Purified PMNs of healthy (B) and glibenclamide-treated diabetic (C) subjects were treated with glibenclamide at concentrations as indicated for 1 h and stimulated by *B. pseudomallei* (MOI 0.3:1), LPS (300 ng/ml), and PMA (3 ng/ml) for 16 h. IL-1β and IL-8 levels in supernatants were measured. Data are expressed as means ± s.d. and represent one of the three independent experiments with similar results. Asterisks indicate significant differences between glibenclamide-treated and no glibenclamide groups by Two Way ANOVA. \*\*\**P* \< 0.001 \*\**P* \< 0.01, and \**P* \< 0.05. No asterisk or ns, non significant.](srep03363-f4){#f4}

![Decreased IL-1β and IL-8 production is associated with glibenclamide treatment.\
IL-1β and IL-8 levels in supernatants were assessed at 16 h after purified PMNs from five subject groups as mentioned infected with *B. pseudomallei* at an MOI of 0.3:1. Data are expressed as means ± s.d. Asterisks indicate significant differences between not-treated and healthy subjects, and between other DM and not-treated subjects by One Way ANOVA. \*\**P* \< 0.01, and \**P* \< 0.05. No asterisk or ns, non significant.](srep03363-f5){#f5}

###### Primer sequences for real time PCR

  Gene          Forward Primer 5′-3′        Reverse Primer 3′-5′      Size (bp)
  ---------- --------------------------- --------------------------- -----------
  Caspase1    GGAGACATCCCACAATGGGCTCTGT     AGTGGTGGGCATCTGCGCTC         149
  GAPDH        CCGAGCCACATCGCTCAGACAC     ACCAGAGTTAAAAGCAGCCCTGGTG      101
  IL-1β         ACGCTCCGGGACTCACAGCAA     TTGAGGCCCAAGGCCACAGGTATT       164
  IL-8         CGTGGCTCTCTTGGCAGCCTTC     TTTCTGTGTTGGCGCAGTGTGGTC       179
  NLRP3         GGGCGACCTGGGGGTCATGA        GGCAGCCCCGTTTCCACTCC         188

###### General characteristics of diabetic subjects and healthy control groups

                                                                           Diabetic (n = 46)                                                                                  
  ----------------------------------------------------------- ----------- ------------------- --------------------------------------- --------------------------------------- ---------------------------------------
  Total (n = 78)                                                  32               6                            16                                      16                                       8
  Sex ratio (female:male)                                        15:17            2:4                          10:6                                    12:4                                     5:3
  Average age (year)[a](#t2-fn1){ref-type="fn"}                 41 ± 8          48 ± 8           60 ± 9[b](#t2-fn2){ref-type="fn"}      62 ± 10[b](#t2-fn2){ref-type="fn"}      58 ± 14[b](#t2-fn2){ref-type="fn"}
  Fasting blood glucose (mmol/L)[a](#t2-fn1){ref-type="fn"}    5.1 ± 0.9      12.1 ± 2.2       11.2 ± 1.4[b](#t2-fn2){ref-type="fn"}   11.0 ± 2.4[b](#t2-fn2){ref-type="fn"}   10.9 ± 2.9[b](#t2-fn2){ref-type="fn"}
  HbA1c (%)[a](#t2-fn1){ref-type="fn"}                         5.7 ± 0.5       9.1 ± 1.5       9.1 ± 1.0[b](#t2-fn2){ref-type="fn"}    9.3 ± 1.9[b](#t2-fn2){ref-type="fn"}    9.6 ± 2.8[b](#t2-fn2){ref-type="fn"}
  Treatment period (year)[a](#t2-fn1){ref-type="fn"}               0               0                           9 ± 5                                   8 ± 5                                   5 ± 5

^a^The values are means ± s.d.

^b^No statistically significant differences (P ≥ 0.05) compared to no treated diabetic group using One Way ANOVA.
